These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
4. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
5. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884 [TBL] [Abstract][Full Text] [Related]
6. Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET. Chan AW; Moliterno DJ Curr Opin Cardiol; 2001 Nov; 16(6):375-83. PubMed ID: 11704709 [TBL] [Abstract][Full Text] [Related]
7. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506 [TBL] [Abstract][Full Text] [Related]
8. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Ibbotson T; McGavin JK; Goa KL Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074 [TBL] [Abstract][Full Text] [Related]
9. Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction. Velianou JL; Al-Suwaidi J; Mathew V Am J Cardiovasc Drugs; 2002; 2(5):315-22. PubMed ID: 14727961 [TBL] [Abstract][Full Text] [Related]
10. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW; Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213 [TBL] [Abstract][Full Text] [Related]
11. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ; N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304 [TBL] [Abstract][Full Text] [Related]
12. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]
14. Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. Roe MT; Moliterno DJ J Thromb Thrombolysis; 1999 Jun; 7(3):247-57. PubMed ID: 10373718 [No Abstract] [Full Text] [Related]
15. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636 [TBL] [Abstract][Full Text] [Related]
16. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty]. Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204 [TBL] [Abstract][Full Text] [Related]
17. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R; JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998 [TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346 [TBL] [Abstract][Full Text] [Related]
20. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Ibbotson T; McGavin JK; Goa KL Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]